Cancer of breast

Breast cancer is the second most commonly diagnosed cancer worldwide, behind only lung cancers; this is even more remarkable when its relative rarity in males is noted (males


Read more on Cancer of breast



Latest news articles

Added 2 months ago Drug news

Mylan and Biocon launch Ogivri in the US, being the first biosimilar trastuzumab approved by the FDA.

Mylan N.V. and Biocon Ltd. announced the U.S. launch of Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab). Ogivri is available...

Added 4 months ago Drug news

Herzuma and Truxima biosimilars to be distributed in Australia by Celltrion and to hospitals by Juno Pharmaceuticals.

Celltrion Healthcare (Celltrion) has entered into a partnership with Juno Pharmaceuticals (Juno) ( not to be confused with Juno Therapeutics)...

Added 4 months ago Drug news

Seattle Genetics initiates phase III trial ( HER2CLIMB-02) of tucatinib + ado-trastuzumab emtansine to treat metastatic HER2-positive (HER2+) breast cancer.

Seattle Genetics, Inc. announced dosing of the first patient in HER2CLIMB-02, a randomized phase III clinical trial evaluating investigational agent...

Search all news articles for Cancer of breast

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.



See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more


Early Breast Cancer: ESMO Clinical Practice Guidelines

These updated ESMO Clinical Practice Guidelines provide updated state-of-the-art recommendations on management of early breast cancer (diagnosis, treatment and follow-up), compiled by a multidisciplinary author panel...

Added 6 months ago

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

The ESO-ESMO 4th international consensus guidelines for advanced breast cancer (ABC 4) focus on methodology, assessment guidelines and treatment recommendations for specific breast cancer subtypes...

Added 1 year ago

Advanced breast cancer: diagnosis and treatment

This guideline covers care and support for people with advanced (stage 4) breast cancer.

Added 11 years ago

Search all guidelines for Cancer of breast

Journal articles

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

Purpose: Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA...

Added 5 months ago

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Background: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2).

Added 5 months ago

Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.

Poly-ADP-ribosyl polymerase (PARP) enzymes PARP-1 and PARP-2 recognize DNA damage and set off a cascade of cellular mechanisms required for multiple types of DNA damage repair. PARP inhibitors are small molecule...

Added 5 months ago

Search all journal articles for Cancer of breast

Clinical trials

Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)

This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of...

Added 7 months ago

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)

This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin) + cyclophosphamide followed...

Added 7 months ago

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Brief Summary:
This study will compare DS-8201a to physician choice standard treatment.
Participants must have HER2-low breast cancer that has been treated before.

Added 7 months ago

Search all clinical trials for Cancer of breast

Blog Posts

Advances in Precision Cancer Care

ESMO 2018 | Day 4 highlights

Posted 1 year ago

In our final report from ESMO 2018 we share insights from the Proffered paper session - Gastrointestinal tumours, colorectal, moderated by Dirk Arnold (Hamburg, DE) and Alfredo Falcone (Pisa, IT). Here, we cover survival data from the MODUL trial, comparing maintenance fluorouracil-bevacizumab and fluorouracil-bevacizumab plus atezolizumab in BRAF wild-type disease, and [in TRIBE2] consider the impact on PFS2 of an intensified treatment strategy versus a standard, sequential treatment strategy.

Advances in Precision Cancer Care

ESMO 2018 | Day 3 highlights

Posted 1 year ago

Sunday’s ESMO 2018 report comes from Presidential Symposium 2, moderated by Fortunato Ciardiello (Napoli, IT) and Josep Tabernero (Barcelona, ES). Here, we share key data and discussions from presentations on the STAMPEDE trial, looking at the role of prostate radiotherapy for patients with newly diagnosed metastatic prostate cancer and JAVELIN Renal 101, assessing avelumab plus axitinib as a first-line treatment option for patients with advanced renal cell carcinoma. 

Advances in Precision Cancer Care

ESMO 2018 | Day 2 highlights

Posted 1 year ago

Saturday’s ESMO 2018 report comes from Presidential Symposium 1, moderated by Andrés Cervantes (Valencia, ES) and Josep Tabernero (Barcelona, ES), discussing the scientific results and clinical implications of new data from the phase 3 IMpassion130, PALOMA-3 and SOLAR-1 trials. 


Carcinoma of unknown primary origin: diagnosis and management: putting NICE guidelines into practice

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
Registration required
Subscription fee
Search all CME for Cancer of breast